E7090
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for E7090, covering 2025-12-16 to 2026-03-11. Get the full timeline:
Most recent: Clinical Trial Update: A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer [Phase 1]